Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation

Fig. 2

hRT/IL-2c combination treatment enhances the numbers of tumor-specific CD8+ T cells in the CD133-B16 melanoma model. Mice bearing an s.c. B16 melanoma tumor were treated with hRT alone or hRT followed by daily i.p. injections of IL-2 or IL-2c for five consecutive days. One day later, tumor (a), spleen (b), and lymph nodes (c) were collected and analyzed by flow cytometry for total counts of the indicated cell subsets (n ≥ 7). d Examples of the flow cytometry results showing proportions of CD8+ and CD4+ T cells in tumor, spleen, and lymph nodes, after hRT, hRT + IL-2, or hRT + IL-2c. e-g Quantification of IFN-γ- and TNF-α-producing tumor-specific CD8+ cells from tumor, spleen, and lymph nodes after restimulation on IFN-γ-pretreated, irradiated B16-CD133 melanoma cells (n ≥ 4 mice/group)

Back to article page